Core-binding factor AML (CBF-AML), characterized by translocations involving RUNX1 and CBFB genes, is generally associated with a favorable prognosis and reasonable response to high-dose cytarabine post-induction therapy [6]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.